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Abstract 
Purpose: Transcatheter hepatic artery embolization therapy is a minimally invasive alternative for 
treating inoperable liver cancer but recurrence is frequent. Multifunctional agents, however, offer an 
opportunity for tumor eradication. In this study, we were aim to synthesized poly (lactic-co-glycolic 
acid) (PLGA) microspheres encapsulating hollow CuS nanoparticles (HCuSNPs) and paclitaxel 
(PTX) that were then labeled with radioiodine-131 (131I) to produce 131I-HCuSNPs-MS-PTX. This 
compound combines the multi-theranostic properties of chemotherapy, radiotherapy and 
photothermal therapy. In addition, it can also be imaged with single photon emission computed 
tomography (SPECT) imaging and photoacoustic imaging. 
Methods: We investigated the value of therapeutic and imaging of 131I-HCuSNPs-MS-PTX in rats 
bearing Walker-256 tumor transplanted in the liver. After the intra-arterial (IA) injection of 
131I-HCuSNPs-MS-PTX, 18F-Fluorodeoxyglucose (18F-FDG) micro-positron emission 
tomography/computed tomography (micro-PET/CT) imaging was used to monitor the therapeutic 
effect. PET/CT findings were verified by immunohistochemical analysis. SPECT/CT and 
photoacoustic imaging were performed to demonstrate the distribution of 131I-HCuSNPs-MS-PTX 
in vivo. 
Results: We found that embolization therapy in combination with chemotherapy, radiotherapy and 
photothermal therapy offered by 131I-HCuSNPs-MS-PTX completely ablated the transplanted 
hepatic tumors at a relatively low dose. In comparison, embolization monotherapy or combination 
with one or two other therapies had less effective anti-tumor efficacy. The combination of 
SPECT/CT and photoacoustic imaging effectively confirmed microsphere delivery to the targeted 
tumors in vivo and guided the near-infrared laser irradiation. 
Conclusion: Our study suggests that there is a clinical theranostic potential for imaging-guided 
arterial embolization with 131I-HCuSNPs-MS-PTX for the treatment of liver tumors. 
Key words: 131I-hollow copper sulfide nanoparticles-microsphere-paclitaxel (131I-HCuSNPs-MS-PTX), 
multifunctional, positron emission tomography/computed tomography (PET/CT), embolization. 
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Introduction 
Liver cancer is the sixth most common cancer 
and the third leading cause of cancer-related mortality 
worldwide [1]. Across metastatic disease, liver 
metastases are seen in 25% of cases [2]. Clinically, only 
a small number of patients (9-27%) have the 
opportunity for surgery [3]. The standard approaches 
to liver cancer include surgical resection, liver 
transplantation and locoregional therapies including 
radiofrequency ablation (RFA), transarterial 
chemoembolization (TACE) and percutaneous 
ethanol injection (PEI) [4, 5]. The rate of tumor 
recurrence, however, following RFA or PEI is high [6, 
7]. Some investigators have reported that combined 
locoregional therapy using RFA with TACE improves 
outcomes when compared to RFA alone [8, 9]. 
Conventional TACE (cTACE) usually consists of 
the intra-arterial (IA) infusion of a chemotherapeutic 
agent mixed with lipiodol and then embolic particles. 
Lipiodol has poor control over drug release [10]. 
Recently several investigators have shown that unlike 
the rapid release of the drug from lipiodol in cTACE, 
drug-eluting beads (DEB)-TACE can release drugs in 
a controlled and sustained way [11-13]. DEB-TACE 
has some limitations: a) there is a lack of imaging 
feedback to allow direct and precise delivery of the 
therapeutic agents to the target site [14]; b) current 
materials are mostly non-biodegradable, which can 
make repeat treatment for tumor recurrence 
problematic. Chemotherapeutic/embolic agents with 
imaging and therapeutic capabilities would overcome 
the limitations of cTACE and DEB-TACE, and 
perhaps provide greater treatment efficacy.  
Recently, several nano/micrometer-sized 
materials have been developed that can serve as 
embolic and drug-delivery agents with high tumor 
uptake after IA injection and less potential damage to 
surrounding tissues [15, 16]. In addition, 
nanomaterials with intense photothermal coupling 
effects have been identified for near-infrared (NIR) 
laser-induced photothermal therapy (PTT) of tumors 
in preclinical studies [17-19]. Moreover, these 
nanoparticles are versatile with the ability to cater for 
diagnosis and therapy with temporally- and 
spatially-controlled drug delivery [20, 21], 
photoacoustic imaging [22, 23], and nuclear medicine 
imaging and therapy [24, 25]. Semiconductor CuS 
nanoparticles are a new class of photothermal 
coupling agents. The NIR absorption by CuS 
nanoparticles is derived from the d–d transition of 
Cu2+ ions, which is not affected by the solvent or the 
surrounding environment [26, 27]. The hollow CuS 
nanoparticles (HCuSNPs) have controlled drug 
release [28] and are suitable for photoacoustic 
imaging [29, 30]. 64Cu-labeled CuS nanoparticles have 
been pre-clinically applied to positron emission 
tomography–computed tomography (PET/CT) 
imaging [31, 32] and radiotherapy [33]. Unlike gold 
nanostructures that are non-biodegradable, HCuSNPs 
are excreted from the liver and kidneys and are 
considered biodegradable [28, 34, 35]. Due to the 
extremely low solubility of CuS, CuS nanoparticles 
show much less toxicity than CuO nanoparticles [36]. 
Our aim was to investigate HCuSNPs-loaded 
microspheres, which combine photothermal, chemo- 
and radio-therapies with photoacoustic imaging and 
single photon emission computed 
tomography/computed tomography (SPECT/CT) 
imaging, delivered by arterial embolization in a single 
setting (Figure 1A) to Walker-256 tumor transplanted 
in rat liver. We incorporated HCuSNPs, as 
photothermal coupling agents, into poly 
(lactic-co-glycolic acid) (PLGA) microspheres to 
produce HCuSNPs-loaded microsphere 
(HCuSNPs-MS). The HCuSNPs-MS was labeled with 
iodine-131 (131I) for SPECT/CT imaging and 
radiotherapy. Paclitaxel (PTX) was loaded into the 
microspheres for chemotherapy. We hypothesized 
that PTX-loaded and 131I-labeled HCuSNPs-MS 
(131I-HCuSNPs-MS-PTX) would have a combined 
therapeutic effect on the hepatic tumors (Figure 1B) 
and allow for SPECT/photoacoustic imaging to 
monitor the delivery of the microspheres in vivo. 
Materials and Methods  
Chemicals 
Sodium sulfide (Na2S), copper chloride (CuCl2) 
and sodium perchlorate (NaClO4) were supplied by 
Sigma-Aldrich (Saint Louis, MO, U.S.A.). Polyvinyl 
alcohol (PVA; MW ~74885, 88% hydrolyzed) was 
purchased from Aladdin (Shanghai, China). PLGA 
(lactide: glycolide = 50:50, viscosity = 0.55-0.75 dL/g) 
was purchased from Durect (Cupertino, USA). PTX 
was provided by Melone Pharmaceutic (Dalian, 
China). Na131I was obtained from XinKe Corporation 
(Shanghai, China). Deionized water was obtained 
from a Milli-Q synthesis system (Millipore, Billerica, 
MA). 
Preparation and characteristics of 
HCuSNPs-MS-PTX  
HCuSNPs were synthesized according to the 
previously reported procedures [37]. PLGA 
microspheres (40 µm) containing PTX and HCuSNPs 
were prepared as follows: Briefly, an aqueous solution 
(0.2 mL) containing 3.2 mg of HCuSNPs was mixed 
with dichloromethane (2 mL) containing 50 mg of 
PLGA and 2.5 mg of PTX by the ultrasonic probe 
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(Scientz, China) to form the first emulsion. Then the 
emulsions were added to 2% polyvinyl alcohol (PVA) 
solution serving as the external aqueous phase, and 
homogenized to form a w1/o/w2 multiple emulsion. 
The emulsion was then poured into 0.5% PVA 
solution and stirred at 1000 rpm for 3 h using 
magnetic stirrer to evaporate the dichloromethane 
completely. Finally, the microspheres were separated 
by centrifugation at 3214 g for 10 min and the 
precipitate was washed three times with deionized 
water. 
The morphology of the HCuSNPs and 
microspheres were measured by transmission 
electron microscopy (TEM, VEGA TS5136MM, 
TESCAN s.r.o., Brno, Czech Republic) and scanning 
electron microscopy (SEM, Tecnai G2 20 TWIN, FEI 
company, Hillsboro, USA). The size distributions of 
HCuSNPs and microspheres were measured by 
Zetasizer Nano-90 and Malvern Matersizer 3000 
(Malvern, UK), respectively. The UV-visible spectra 
were measured by UV-2401PC UV/vis 
spectrophotometer (Shimadzu, Japan).  
A 915-nm NIR laser light (MDL-III-915R, CNI, 
Changchun, China) was delivered through a quartz 
cuvette, containing HCuSNPs phosphate buffer saline 
(PBS) solution (1 mg/mL, 200 μL), HCuSNPs-MS PBS 
solution (23.98 mg/mL of MS containing 1 mg/mL of 
HCuSNPs, 200 μL) and PBS solution (200 μL) at an 
output power of 0.5 W/cm2 over a period of 10 min to 
measure the photothermal effect of HCuSNPs-MS. 
The temperature was measured by a thermocouple, 
which was inserted into the solution during laser 
exposure. Long-term release of PTX from 
HCuSNPs-MS-PTX was investigated. The sample was 
prepared by suspending HCuSNPs-MS-PTX to form 
0.55 mg/mL of MS (PTX, 25 µg/mL) solution with 
0.5% Tween 80. Then MS solution (200 µL) was 
aspirated and added to an EP vial. The vials were kept 
in a 37 °C water bath. Three vials were centrifuged at 
13523 g for 10 min at each time point. PTX 
concentration in the supernatant was measured by a 
high performance liquid chromatography (HPLC) 
system (LC-20AR, Shimadzu, Japan) with an 
SPD-M20AV photodiode array detector (Shimadzu, 
Japan). Additionally, NIR-light-triggered release of 
PTX from PLGA microspheres was performed. In 
brief, a HCuSNPs-MS-PTX precipitate (5.57 mg) or a 
MS-PTX precipitate suspended with PBS (0.01 M, 200 
μL, pH 7.4) containing Tween 80 (0.5%, w/v) were 
aspirated into a quartz cuvette, respectively and 
irradiated using 915-nm NIR laser light (0.5 W/cm2, 5 
min) followed by 1.5 h intervals with the laser turned 
off and repeated three times. Before and after 
exposure each time, the solution was centrifuged at 
3214 g for 5 min, and the supernatant was collected 
for free PTX determination. Then a fresh solution (200 
μL) was added to suspend the precipitate for the next 
procedure. The HCuSNPs-MS-PTX solution without 
laser exposure was used as a control.  
 
 
Figure 1. A, Schema shows structure of 131I-HCuSNPs-MS-PTX. B, Outline of 131I-HCuSNPs-MS-PTX for combined hepatic tumor arterial embolization in a rat liver 
tumor: Step 1, arterial embolization; Step 2, multimodal theranostics.  
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X-ray photoelectron spectroscopy (XPS) 
(PHI 5500, Perkin-Elmer, USA) was used to measure 
the surface elemental composition of the microsphere 
powders. The morphology of the cross-section of 
microspheres was observed by SEM. The loading 
efficiency of HCuSNPs in HCuSNPs-MS-PTX and 
HCuSNPs-MS was calculated by inductively coupled 
plasma optical emission spectrometry (ICP-OES) 
(ICAP6000, ThermoFisher Scientific, USA) analysis. 
For ICP-OES analysis, the microspheres solution was 
digested using a WX-6000 microwave system 
(PreeKem Corporation, Shanghai, China). In brief, ~10 
µL of samples (50 mg/mL) were transferred into 
digestion vessels. After adding nitric acid (5 mL) to 
each vessel, the samples were digested for 20 min at 
200 °C. Afterwards, the digested solution was 
evaporated to nearly dry and diluted with deionized 
water to a 10 mL of final volume for ICP-OES analysis. 
Radiolabeling with 131I  
HCuSNPs-MS-PTX solution (0.2 mL, 12.5 mg) 
containing 0.72 ×1011 of HCuSNPs was mixed well 
with Na131I solution (0.2 mL, 37 MBq) and sodium 
perchlorate solution (NaClO4) (0.8 mL, 0.1 mM), and 
then the mixture was incubated for 40 min at 32 °C. 
After adding deionized water (0.8 mL), the mixture 
was centrifuged at 67 g for 8 minutes at room 
temperature to rinse free Na131I. The precipitate was 
suspended in normal saline solution (80 µL) to yield 
the final product. The radiolabeling yield was 
measured by thin-layer chromatography (TLC) using 
Whatman No.1 filter paper and deionized water was 
used as a developing solvent. The labeled 
microspheres remained at the original spot, while free 
131I ions shifted to the strip front. Then the filter paper 
was cut into two sections and each section was 
measured for radioactivity using a gamma counter 
(SN-697, Shanghai Institute of Nuclear Research, 
Rihuan Instrument Factory, Shanghai, China). The 
result was expressed as percentage of radioactivity of 
131I-HCuSNPs-MS-PTX relative to all radioactivity. 
The stability of radiolabeled 131I-HCuSNPs-MS-PTX in 
serum was analyzed by incubating 
131I-HCuSNPs-MS-PTX in fetal bovine serum (FBS) 
(1:1, v/v) at 37 °C. The radiolabeling yield was 
measured by TLC at 1 h, 2 h, 4 h, 6 h, 12 h, 24 h, 48 h 
and 72 h, respectively. 
Animal preparation  
All the experiments were approved by Ren Ji 
Institutional Animal Care. Male Sprague Dawley rats 
(200-250 g) were purchased from Ren Ji Hospital 
Experimental Animal Center (Shanghai, China). Rats 
were kept under a specific pathogen-free condition at 
the laboratory animal center. To evaluate the 
biodistribution and therapeutic efficacy of 
131I-HCuSNPs-MS-PTX, we established Walker-256 
tumor transplanted in rat liver [38]. Tumor 
transplantation was performed as follows: Walker-256 
cells (5 × 106, 150 µL) were firstly injected 
subcutaneously in a donor rat. When the tumor 
diameter reached 6-8 mm, it was explanted from the 
donor rat and minced into small cubes of about 1 
mm3. The solid tumor fragment was inserted into the 
right liver lobe of the recipient rats. Ten days later, we 
performed 18F-FDG micro-PET/CT scans to 
investigate the size of the liver tumor and when the 
diameter of liver tumor reached 6-8 mm, it was ready 
for the experiment. 
Arterial Cannulation 
Figure 2 represents the process of transcatheter 
arterial administration of 131I-HCuSNPs-MS-PTX 
under a surgical microscope (Leica Microsystems, 
Weitzlar, Germany) according to a published method 
[38]. The celiac, hepatic and gastroduodenal arteries 
were identified and carefully dissected. Then two 
ligatures were placed around gastroduodenal artery 
and the distal part of the gastroduodenal artery was 
ligatured. A ligature was placed around the celiac 
artery to temporarily interrupt arterial flow. The 
gastroduodenal artery was punctured upstream of the 
distal ligature using a self-made needle and then a 
catheter was placed into the hepatic artery. After the 
administration of the microspheres, the proximal part 
of the gastroduodenal artery (upstream of the 
puncture point) was tied off. The ligature around the 
celiac artery was removed and hepatic arterial flow 
was restored. 
Biodistribution and CuS staining 
Three rats with transplanted tumors were given 
IA injection with 131I-HCuSNPs-MS-PTX (80 μL, 10 
mg, containing 0.5 mg of PTX, 0.58 ×1011 of HCuSNPs 
and 28 MBq of 131I) to determine the distribution of the 
compound. Four hours post-administration, the rats 
were euthanized by inhalation of carbon dioxide. 
Blood, thyroid, lung, heart, spleen, stomach, intestine, 
colon, kidney, bladder, brain, bone, liver and the 
tumor were excised, weighed, and their radioactivity 
were measured by a gamma counter (SN-697, 
Shanghai Institute of nuclear research, Rihuan 
Instrument Factory, Shanghai, China). The organ 
uptake of 131I-HCuSNPs-MS-PTX was calculated as 
%ID/g. To validate the copper distribution in the liver 
tumor, another 6 rats with transplanted tumors were 
randomly assigned to 2 groups (n = 3 in each group). 
All had IA injection with HCuSNPs-MS-PTX (80 μL, 
10 mg, containing 0.5 mg of PTX and 0.58 ×1011 of 
HCuSNPs). One group was euthanized at 1 h 
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post-injection and the second group was euthanized 
at 4 h post-injection. The tumors were snap-frozen 
and then sectioned into contiguous 5-μm slices. A 
5.0% silver nitrate aqueous solution (solution A) was 
used for CuS staining. An aqueous solution 
containing 2% hydroquinone and 5% citric acid was 
prepared as solution B. The slices were deparaffinized 
with xylene and graded alcohols and then exposed to 
freshly filtered solution that comprised 1 part solution 
A and 5 parts solution B for 3 min. The slices were 
then deionized with a water wash and then 
counterstained with hematoxylin. 
 
 
Figure 2. Intra-arterial injection of 131I-HCuSNPs-MS-PTX via hepatic artery in 
rats bearing Walker-256 tumor transplanted in the liver. Tumor was observed 
under a surgical microscope (magnification 16 x). A, Liver tumor (yellow 
arrow). B, Coeliac, hepatic and gastroduodenal arteries were identified and the 
gastroduodenal artery (yellow arrow) was ligated with two sutures; the thread 
interrupts coeliac arterial flow temporarily. C, The gastroduodenal artery was 
punctured ‘upstream’ and a cannula was placed into the hepatic artery (yellow 
arrow). D, After the administration of the microspheres, the proximal 
gastroduodenal artery was tied off and the thread around the coeliac artery was 
removed. 
 
Evaluation of the additional anticancer effect 
of the microspheres 
The rats with transplanted tumors were 
randomly assigned to 6 groups (n = 5 in each). All rats 
received IA injections. The 6 groups (A-F) were as 
follows. Group A rats were injected with saline 
(control group, 80 μL). Group B rats were injected 
with 131I-HCuSNPs-MS-PTX following laser 
irradiation (80 μL, 10 mg, containing 0.5 mg of PTX, 
0.58 × 1011 of HCuSNPs and 28 MBq of 131I). Group C 
rats were injected with 131I-HCuSNPs-MS-PTX (80 μL, 
10 mg, containing 0.5 mg of PTX, 0.58 × 1011 of 
HCuSNPs and 28 MBq of 131I). Group D rats were 
injected with HCuSNPs-MS-PTX following laser 
irradiation (80 μL, 10 mg, containing 0.5 mg of PTX 
and 0.58 × 1011 of HCuSNPs). Group E rats were 
injected with 131I-HCuSNPs-MS (80 μL, 10 mg, 
containing 0.58 × 1011 of HCuSNPs and 28 MBq of 131I) 
following laser irradiation. Group F rats were injected 
with 131I-HCuSNPs-MS (80 μL, 10 mg, containing 0.58 
× 1011 of HCuSNPs and 28 MBq of 131I). The NIR laser 
light had an output power of 0.5 W/cm2 over a 5 min 
period. Laser irradiation was conducted at 4 h 
post-injection under the guide of photoacoustic 
imaging. We used an infrared thermal imaging 
camera (DT-980, CEM, Shanghai, China) during laser 
exposure to measure the tumor temperature over 6 
min in each group.  
18F-FDG micro-PET/CT imaging  
We used a micro-PET/CT scanner (Super Nova® 
PET/CT, PINGSENG Healthcare Inc., Shanghai, 
China) to measure 18F-FDG uptakes in the rats. 
PET/CT scans were acquired at baseline prior to 
treatment and 1 d, 2 d, 4 d and 7 d post-injection of 
saline or microspheres. The spatial resolution of the 
PET/CT scanner is ~0.6 mm and the resolution of the 
CT is 0.2 mm. 18F-FDG (0.3 mL, 37 MBq) was injected 
into the tail vein; the uptake period was 60 min and 
scan duration was 30 min. Rats were maintained 
under anesthesia with 2% isoflurane during scan 
acquisition. PET images were reconstructed with the 
ordered-subsets expectation maximization (OSEM) 
algorithm using 16 subsets and 4 iterations. An 
irregular region of interest, which covered the entire 
tumor, was drawn on the CT and then copied to the 
co-registered PET using Avatar 1.2 software 
(Pingseng, Shanghai, China). We measured the 
maximum transaxial diameters (length, width) of the 
tumors and the maximum standard uptake value 
(SUVmax). Tumor volumes were calculated as 0.5 × 
length × width2 (mm3) [39]. 
Histopathology and immunohistochemical 
staining 
The animals were euthanized after 18F-FDG 
micro-PET/CT scan on day 7. The tumors were 
harvested, snap-frozen with optimum cutting 
temperature compound (O.C.T., Sakura, San 
Francisco, USA) and then sectioned into 6 contiguous 
5-µm slices. Two slices were stained with hematoxylin 
& eosin (H&E). Four slices were stored at -80 °C for 
immunohistochemical staining. Two slides were 
stained with terminal dexynucleotidyl transferase 
(TdT)-mediated dUTP nick end labeling (TUNEL) 
(Yeasen, Shanghai, China) according to the 
manufacturer’s protocol. TUNEL-stained slides were 
analyzed under a fluorescence microscope (Zeiss Axio 
Observer.Z1, Oberkochen, CARL ZEISS, Germany). 
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Two slides were stained with anti-active Ki-67 
polyclonal antibody according to the manufacturer’s 
protocol (Novus, Colorado, USA). In addition, major 
organs (liver, kidney, spleen and lung) of rats in each 
group were dissected, embedded in O.C.T., snap 
frozen, and sectioned in 5-μm thick slices. The slices 
were stained with H&E for histological analysis. 
Photoacoustic imaging and SPECT/CT 
imaging 
The rats treated with 131I-HCuSNPs-MS-PTX (80 
μL, 10 mg, containing 0.5 mg of PTX, 0.58 × 1011 of 
HCuSNPs and 28 MBq of 131I) plus laser irradiation 
underwent SPECT/CT imaging at 1 h, 4 h, 24 h, 48 h 
and 72 h post-injection. All rats were given water 
containing 0.12% potassium iodide (0.1 g of KI was 
added to 100 mL of drinking water) from 3 d before 
SPECT/CT imaging to minimize thyroid uptake of 
free 131I. The SPECT/CT scanner (Precedence 6, Philip 
Medical Systems, Netherlands) had a variable-angle 
dual-detector with high-resolution collimators and a 
multislice spiral CT. The SPECT acquisition (128 × 128 
matrix, 30 frames) was performed using 6° angular 
steps in 25 s time frames. After reconstruction, SPECT 
images were corrected for attenuation and scatter. CT 
scans were performed using a multislice CT scanner 
(PHILIPS Precedence, Philip Medical Systems, 
Netherland, 120 kV, 240 mA, 1 mm per scan). 
Reconstruction of transaxial slices was performed 
using filtered back projection (Metz filter power, 3.00; 
full width at half maximum, 10 mm) with subsequent 
attenuation correction using the Chang method 
(attenuation coefficient 0.12). SPECT/CT images were 
fused using Syntegra software (Philip Medical 
Systems, Netherlands).  
Another three Rats that were injected with 
131I-HCuSNPs-MS-PTX underwent photoacoustic 
imaging. The rats were maintained under anesthesia 
with 1% isoflurane. The photoacoustic scans were 
conducted at 1 h, 2 h, 3 h and 4 h post-injection using a 
Vevo 2100 ultrasound/photoacoustic (PA) scanner 
with a LZ400 PA probe (30 MHz linear acoustic array 
transducer; VisualSonics Inc., Toronto, Canada). The 
tumor was located by B-mode (ultrasonic scan) and 
PA-mode. Clear gel was centrifuged (to remove air 
bubbles) and used to provide PA coupling between 
the probe and tumor. PA-mode was conducted in 
nanostepper mode using several laser wavelengths: 
750 nm, 810 nm, 850 nm, 855 nm, 895 nm and 915 nm. 
A spectroscopically-separated multiplexer was used 
for data analysis in Vevo LAB software. Multispectral 
photoacoustic imaging was also performed to obtain 
measurements of hemoglobin. All imaging datasets 
were analyzed using the Vevo LAB (Ver 1.7.2) 
workstation software. 
Statistical analysis 
Group variation was described as the mean ± 
standard deviation (SD). The difference in tumor 
volume and SUVmax values on day 7 among multiple 
treatment groups was evaluated by one-way analysis 
of variance (ANOVA) followed by least-significant 
difference (LSD) post hoc multiple comparison tests 
(SPSS 22.0, USA). Differences between groups were 
considered statistically significant at p < 0.05, and p < 
0.001 was considered highly statistically significant. 
Results  
Characterization of the synthesized 
microspheres 
TEM images of HCuSNPs showed that the 
nanoparticles with hollow interior had a uniform size 
of 198.36 nm ± 4.85 nm in diameter (Figure 3A and B). 
The HCuSNPs had a peak absorbance intensity at 900 
nm (Figure 3C). Following NIR light exposure (0.5 
W/cm2, 10 min), the temperature of PBS containing 
HCuSNPs-MS increased from 25.6 °C to 57.7 °C (ΔT = 
32.1 °C) owing to the strong photothermal conversion 
effect of HCuSNPs incorporated in the microspheres 
(Figure 3D). In comparison, the temperature of PBS 
following laser irradiation did not obviously change.  
The microspheres had an average size of 47.27 
µm ± 0.5 µm (Figure 3E and F). The size of the 
microspheres can be controlled by stirring speed. The 
microspheres with mean sizes of 24.3 µm, 47.2 µm, 
and 76.6 µm were acquired under stirring at 1500 rpm, 
1000 rpm and 500 rpm by magnetic stirrer, 
respectively. The loading content of HCuSNPs and 
loading efficiency of PTX in HCuSNPs-MS-PTX and 
HCuSNPs-MS are presented in Table 1. PTX was 
readily loaded into PLGA microspheres with > 95% 
encapsulation efficiency (Table 1). PTX release profile 
revealed a sustained and slow release of PTX from the 
PLGA microspheres with a cumulative release of 
4.23% ± 0.92% at day 1 and 41.77% ± 3.78 % at day 7, 
without significant burst release (Figure 3G). A rapid 
release of PTX from HCuSNPs-MS-PTX was achieved 
when triggered by NIR light (Figure 3H). The light 
(0.5 W/cm2, 915 nm) triggered ~3-4-fold of PTX 
release from HCuSNPs-MS-PTX within 5 min 
compared to the PTX release from the same 
microspheres for the initial 1.5 h but without laser 
irradiation. No rapid increase of PTX release was 
observed when PTX-MS was exposed to the laser, 
indicating that the photothermal effect mediated by 
HCuSNPs accelerated the release of PTX.  
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Figure 3. A, Transmission electron microscopy images of HCuSNPs. Bar, 100 nm. B, Size distribution of HCuSNPs. C, Absorbance spectrum of HCuSNPs in water. 
D, Temperature-time profiles of HCuSNPs-MS in PBS (200 μL, 23.98 mg/mL of MS containing 1 mg/mL of HCuSNPs), HCuSNPs in PBS (200 μL, 1 mg/mL) and PBS 
(200 μL) under NIR laser irradiation (915 nm, 0.5 W/cm2, 10 min). Red arrow indicates laser switched on. E, Scanning electron microscopy images of 
HCuSNPs-MS-PTX. Bar, 20 µm. F, Size distribution of HCuSNPs-MS-PTX. G, Cumulative release of PTX from HCuSNPs-MS-PTX. H, NIR light-triggered release of 
PTX from HCuSNPs-MS-PTX. NIR laser light (915 nm, 0.5 W/cm2, 5 min). Red arrows indicate laser switched on. I, Scanning electron micrographs of the 
cross-section of HCuSNP-MS-PTX. Bar, 10 µm. J, K, Enlarged area in (I). L, SEM image of HCuSNPs. Bars in (J), (K) and (I), 200 nm. 
 
Table 1. Characteristics of the microspheres. 
Microspheres HCuSNPs loading 
(w/w,%) 
Encapsulation efficiency 
of PTX loading (%) 
HCuSNPs-MS-PTX 3.18 ± 0.27 96.75 ± 0.42 
MS-PTX ---- 99.36 ± 0.03 
HCuSNPs-MS 4.17 ± 0.10 ---- 
 
 
The XPS lineshapes reveal that the two peaks 
located at 932.2 eV and 952.2 eV are assigned to Cu 
2p3/2 and Cu 2p1/2 of HCuSNP, respectively. The 
peak at 162 eV corresponds to S 2p of HCuSNP. By 
contrast, there were no peaks detected in MS and 
MS-PTX powders without HCuSNP-loading (Figure 
S1). The SEM images showed many pores spreading 
over the cross-section of the microspheres, which 
were probably formed during the drying process of 
the internal water phase (Figure 3I). It was obvious 
that the HCuSNPs existed in the pores (Figure 3J, K 
and L). These SEM images evidenced that HCuSNPs 
were successfully loaded into the microspheres.  
In the previous report [40], copper (I) sulfide 
could absorb iodide by replacing hydroxyl groups on 
the surface (Equation 1), similar to what was observed 
for adsorption of iodide on Cu2O in neutral or alkaline 
medium. The Cu/S compositional ratio (63.49%: 
36.51%) of HCuSNPs detected by scanning electron 
microscopy-energy dispersive spectrometry (SEM- 
EDS) indicated that there was copper (I) sulfide in 
HCuSNPs. 131I thus can be labeled on the HCuSNPs 
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through formation of copper (I)-iodide complexes. 
The radiolabeling yield and specific activity of 
131I-HCuSNPs-MS-PTX were ~97% and ~2.9 
MBq/mg, respectively. The final radioactivity 
concentration of 131I-HCuSNPs-MS-PTX was ~0.45 
MBq/µL. Finally, we measured 131I-HCuSNPs- 
MS-PTX (12.5 mg, 80 μL) containing 0.63 mg of PTX, 
0.73 × 1011 of HCuSNPs and 35 MBq of 131I. The 
radiolabeling yield remained at 97% in saline after 24 
h, whereas, the radiolabeling yield of 
131I-HCuSNPs-MS-PTX in serum remained at ~70.2% 
at 48 h.  
Equation 1. The mechanism for 131I labeling of 
the HCuSNPs: 
 
 
  
Distribution of 131I-HCuSNPs-MS-PTX 
following transcatheter arterial embolization  
Biodistribution results showed that at 4 h 
post-injection, the tumor uptake of 
131I-HCuSNPs-MS-PTX was as high as 3.15 %ID/g ± 
0.49 %ID/g (Figure 4A). IA injection of 
131I-HCuSNPs-MS-PTX resulted in higher 
nanoparticle accumulation in the tumor than in 
normal liver tissues (tumor-to-liver ratio 1.41 ± 0.14). 
Remarkably, lung uptake of 131I-HCuSNPs-MS-PTX 
was only 0.30 %ID/g ± 0.05 %ID/g. Tumor-to-lung 
ratio of 131I-HCuSNPs-MS-PTX was 7.58 ± 1.76 and the 
rats did not display tachypnea, cyanosis, tachycardia 
or acute death after injection, indicating that the IA 
injection did not produce pulmonary embolism. 
Moreover, 131I-HCuSNPs-MS-PTX showed lower 
retention in the stomach, spleen and thyroid gland. To 
confirm the embolization effect of the 
HCuSNPs-MS-PTX, we stained the CuS of the 
microspheres in the rat liver sections with the 
transplanted tumors following IA administration. 
Figure 4B shows that the IA-administered 
HCuSNPs-MS-PTX filled the blood vessels in tumor 
marginal zones in clusters at 1 h or 4 h following 
injection. At 4 h post-injection there was tumor 
necrosis in the region of tumor surrounding the 
microspheres (Figure 4B). The histological results 
indicated that HCuSNPs-MS-PTX efficiently 
embolized transplanted liver tumor causing tumor 
necrosis at 4 h post-injection. 
Combinatorial anticancer effect of 
131I-HCuSNPs-MS-PTX 
Infrared thermal imaging of the treated 
tumor-bearing rats showed tumor temperature 
quickly elevated from 35.2 °C to 43 °C within 1 min 
upon NIR laser exposure (0.5 W/cm2, 915 nm) then 
gradually reaching a plateau of ~45 °C (Figure 5). In 
contrast, the tumor-bearing rats treated with 
131I-HCuSNPs-MS-PTX but without laser exposure 
did not show any change of temperature. 
 
 
Figure 4. A, Biodistribution of 131I-HCuSNPs-MS-PTX at 4 h post intra-arterial (IA) injection. *p < 0.05, significant difference in values between the two groups. Data 
are presented as mean ± SD. n = 3. B, CuS staining of Walker-256 tumor transplanted in rat liver at 1 h and 4 h post IA injection. Purple dotted lines, 
HCuSNPs-MS-PTX in capillaries of tumor marginal zones. Red dotted lines, HCuSNPs-MS-PTX in tumor necrotic area with marked loss of tumor cell nuclei. T, 
tumor. N, necrotic region. Bar, 50 μm.  
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Figure 5. A, Thermal imaging of tumor-bearing rats after IA injection with different formulations with or without laser treatment (915 nm, 0.5 W/cm2, 5 min). B, 
Temperature-time profile of tumors following different treatments.  
 
Figure 6A illustrates the experimental design to 
evaluate the combinatorial therapeutic effect of 
131I-HCuSNPs-MS-PTX in rats bearing Walker-256 
tumor transplanted in liver. We used 18F-FDG 
micro-PET/CT imaging to monitor the tumor 
response following different treatments. 
Representative 18F-FDG micro-PET/CT images 
showed that tumoral 18F-FDG uptake increased in the 
control group that was not treated (Figure 6B). 
131I-HCuSNPs-MS-PTX plus laser treatment produced 
a significant (p = 0.016, p < 0.05) reduction in 18F-FDG 
uptake in the tumor at 1 d post-treatment. There was 
no 18F-FDG uptake at 7 d post-treatment, consistent 
with an absence of viable tumor. In comparison, 
tumor-bearing rats that were treated with 
HCuSNPs-MS-PTX plus laser irradiation showed 
decreased tumoral 18F-FDG uptake at 1 d 
post-treatment but 18F-FDG uptake quickly increased 
at the tumor marginal site after 2 days, consistent with 
tumor recurrence. 131I-HCuSNPs-MS-PTX and 
131I-HCuSNPs-MS only slowed the tumor growth, 
when compared to the control rats, but were unable to 
stop tumor growth. 
We quantified tumor volume using micro-CT. In 
the control group, there was a marked increase in 
tumor volume from 85.04 mm3 ± 15.46 mm3 (day 0) to 
1015.31 mm3 ± 89.59 mm3 (day 7; Figure 6C); SUVmax 
of tumor increased from 5.61 ± 0.39 to 8.88 ± 0.30 
during 7 d post-treatment (Figure 6D). In contrast, 
there was minimal change in tumor volume in the rats 
treated with 131I-HCuSNPs-MS-PTX and concomitant 
laser exposure between day 0 and day 7 (86.54 mm3 ± 
22.35 mm3 vs. 88.63 mm3 ± 11.66 mm3, p = 0.86; Figure 
6C); SUVmax in the same cohort, however, reduced to 
1.03 ± 0.18, similar to background, at day 7 
post-treatment (Figure 6D), suggesting that the 
tumors were not viable. In comparison, embolization 
in combination with one or two therapy modalities 
slowed but did not stop tumor growth; SUVmax 
decreased within 1 d but quickly recovered at 2 d 
post-injection and further increased after treatment. 
Figure 7A shows photographs of all the liver 
tumors at day 7 after different treatments. Consistent 
with the results of 18F-FDG PET/CT imaging, we 
found that the tumor size of rats treated with 
131I-HCuSNPs-MS-PTX plus laser were the smallest. 
The results of H&E staining, TUNEL and Ki-67 
staining confirmed our 18F-FDG micro-PET/CT 
results (Figure 7B). Tumor cells in the control group 
displayed heteromorphism and heteropyknosis with 
notable increases in nucleus/plasma ratios, high 
expression of Ki-67 and little apoptosis (Figure 7B). In 
the rats treated with 131I-HCuSNPs-MS-PTX plus 
laser, tumor cells displayed characteristics of necrosis 
with complete nuclear loss, little to no expression of 
Ki-67 and marked apoptosis (Figure 7B). In other 
treatment groups, necrosis was localized mostly in the 
center of tumors and Ki-67 was mainly localized to the 
tumor periphery where there were only a few TUNEL 
positive cells (Figure 7B). These results further 
demonstrated that 131I-HCuSNPs-MS-PTX plus laser 
exposure induced marked tumor apoptosis and 
almost complete inhibition of proliferation.  
 Theranostics 2018, Vol. 8, Issue 3 
 
 
http://www.thno.org 
794 
 
Figure 6. A, Experimental design of our combined theranostic approach. B, Representative 18F-FDG micro-PET/CT images. Arrows indicate tumors. C, Tumor 
volumes of different groups at different time-points. D, Tumor SUVmax of different groups at different time-points. SUVmax, maximum standard uptake value. ***p < 
0.001, significant difference in values between the two groups on day 7. Data are presented as mean ± SD. n = 5.  
 
H&E staining (Figure S2) of the major organs 
(liver, kidney, spleen and lung) did not show any 
obvious histopathological abnormalities (i.e., tissue 
damage, inflammation or lesions). Further work is 
needed to systematically study the potential short- 
and long-term toxicity of 131I-HCuSNPs-MS-PTX after 
the IA injections. Furthermore, 131I-HCuSNPs-MS- 
PTX accumulated in tumor blood vessels and 
occluded them 7 d after IA injection (Figure 8). Rats 
treated with 131I-HCuSNPs-MS-PTX plus laser 
showed nearly complete tumor necrosis without 
discernable tumor blood vessels and the microspheres 
were seen in the necrotic tissue but without 
microspheres in the normal liver tissue (Figure 8). 
SPECT/CT and photoacoustic imaging  
SPECT/CT imaging provided the whole-body 
distribution of 131I-HCuSNPs-MS-PTX post IA 
injection of 131I-HCuSNPs-MS-PTX (Figure 9A). 
131I-HCuSNPs-MS-PTX was mainly found in the liver 
tumor and there was minimal uptake in the rest of the 
organs, in particular the lungs. Moreover, the 
SPECT/CT scanning confirmed that the 131I stayed in 
tumors for 48 h following the IA administration 
(Figure 9A). From the photoacoustic images, the 
microsphere distribution in the tumor had 
photoacoustic signal intensities of 0.058 a.u., 0.048 
a.u., 0.064 a.u. and 0.077 a.u. at 1 h, 2 h, 3 h and 4 h 
post-injection, respectively (Figure 9B). 
Discussion 
In this work we developed a multifunctional 
agent that provides TACE and ablation sequentially. 
The present study’s findings validated the 
characteristics of the multifunctional microspheres. 
The PLGA microspheres had high encapsulating 
efficiency of the lipophilic drug PTX, accompanied by 
uniform particle size and a steady drug release rate 
[41]. The incorporated HCuSNPs exhibited a reliable 
photothermal coupling effect independent of the 
microsphere encapsulation, which ensured the 
efficacy of molecular imaging, photothermal therapy, 
drug delivery, and cancer treatment [28, 30, 42]. The 
process of labeling nanoparticles with 131I was simple 
and straightforward, providing feasibility of 
radiotherapy and SPECT/CT imaging [43, 44].  
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Figure 7. A, Photograph of all the liver tumors at day 7 after different treatments. B, H&E, Ki-67 and TUNEL staining following different treatments. Laser, 915 nm, 
0.5 W/cm2, 5 min. Green, TUNEL-positive apoptotic cells. Blue, 4',6-diamidino-2-phenylindole (DAPI)-stained nuclei. Red circle regions, tumors. Bar in red, 5 mm. Bar 
in yellow, 100 μm.  
 
Figure 8. H&E sections from tumor bearing rats treated with microspheres on day 7 showing the normal liver (top left image) and liver tumors (the rest of the 
images). Microspheres were seen in tumor blood vessels and were surrounded by necrotic tissue; microsphere were not seen in normal liver. Yellow arrows, 
microspheres. Bar, 50 μm. 
 
PTX is widely used to treat a variety of cancers 
[45]. Walker-256 tumor (breast cancer) model is rather 
sensitive to PTX [46], so we loaded PTX into the 
microspheres. The laser-triggered release of PTX 
synergized the antitumor effect of PTT since 
hyperthermia potentiated the tumor cell killing effect 
of PTX [47]. Any residual tumor cells remaining after 
laser treatment were eradicated through a combined 
effect of the sustained-released PTX, and the 131I-beta 
rays, which have a tissue penetration of ~2 mm [48]. 
According to our results reported here, tumor can be 
eradicated completely due to the synergistic effect of 
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the above three treatment modalities. 
Our results show that complete inhibition of 
Walker-256 tumor growth in rat liver via IA injection 
of 131I-HCuSNPs-MS-PTX can be achieved at a low 
dose due to the synergistic effects of embolization, 
chemotherapy, PTT, and 131I radiation therapy. 
Embolization of microspheres produced vascular 
occlusion resulting in nutritional tumor deprivation 
[49]. An early study revealed that microparticles less 
than 40 μm in diameter could distribute to 
non-targeted organs, such as the lungs, while 
microparticles larger than 40 μm in diameter were 
mainly trapped in the liver tumor tissue and rarely 
washed out into other organs [50]. In our study, the 
lung distribution of 131I-HCuSNPs-MS-PTX was low 
and the microspheres did not produce pulmonary 
embolism because their average size was 47.27 µm in 
diameter, larger than 40 μm. Localized PTT induced 
tumor ablation; a sublethal dose of hyperthermia at 
the margins of the tumor resulted in tumor 
recurrence, as shown by the relatively high 
metabolism in these areas shown in Figure 6B. 
Incomplete ablation was mainly caused by the ‘heat 
sink’ effect due to the conductive effects of adjacent 
vessels [51]. IA embolization overcomes the heat sink 
effect and improves the effectiveness of TACE-RFA 
[52, 53]. In the clinic, however, the implementation of 
TACE-RFA is complex. 
Although TACE has been the first-line treatment 
for patients with intermediate hepatocarcinoma 
cancer (HCC) for years, there is not a standard global 
approach to the way TACE is used. There are 
variations in technique and embolic and 
chemotherapeutic agents used, which all affect its 
efficacy [54, 55]. A ‘best’ chemotherapeutic/embolic 
agent is yet to be developed. In the clinic, cTACE, 
which typically comprises a mixture of the 
chemotherapeutic in lipiodol (ethiodized poppy seed 
oil), is used to occlude tumor blood vessels and 
release the chemotherapeutic agents. Lipiodol, 
however, may release the drug rapidly and have an 
incomplete embolic effect [56, 57]. When compared to 
the cTACE embolic agents, our agent 
131I-HCuSNPs-MS-PTX has several advantages: a) 
Drug release from the embolic microspheres can be 
controlled by the photothermal effect of the 
nanoparticles. Notably, the microsphere sustained 
release of the chemotherapeutic over time without 
laser exposure. b) The amount of chemotherapy agent 
loaded into the MS can be individually tailored, thus 
allowing for more ‘precise’ and ‘personalized’ 
treatment. c) The diameter of 131I-HCuSNPs-MS-PTX 
is adjustable to achieve effective embolization. d). 
When compared to lipiodol, the size of our 
microspheres allows for easier injection during the 
procedure.  
 
 
Figure 9. A, SPECT/CT scans of tumor-bearing rats after IA injection of 131I-HCuSNPs-MS-PTX (80 μL, 10 mg, containing 0.5 mg of PTX, 0.58 × 1011 of HCuSNPs 
and 28 MBq of 131I) showed that tracer uptake localized to the hepatic tumor (yellow arrow indicates site of tumor). B, Photoacoustic imaging (PAI) of liver in the 
tumor-bearing rats after IA injection of 131I-HCuSNPs-MS-PTX (80 μL, 10 mg, containing 0.5 mg of PTX, 0.58 × 1011 of HCuSNPs and 28 MBq of 131I). Green indicates 
photoacoustic signals of 131I-HCuSNPs-MS-PTX; red reflects photoacoustic signal of hemoglobin.  
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Transcatheter arterial radiation embolization 
(TARE) uses microspheres containing Yttrium-90 (90Y) 
to suppress tumor growth [58, 59], which is well 
tolerated and has a low complication rate due to the 
limited radiation range of beta rays. However, the 
main disadvantage of TARE is that 90Y is unable to 
carry chemotherapeutic agents and the tolerable 
radiation dose of the liver tissue limits retreatment 
with TARE [60]. Although TACE provides a survival 
benefit in patients with intermediate HCC, it may 
result in suboptimal and incomplete tumor responses 
[13]. Further, repeat TACE has the risk of producing 
hepatic dysfunction and reducing patient survival. 
DEB-TACE was developed for transcatheter delivery 
to the liver tumor and it permits sustained drug 
release into the tumor vasculature [61, 62]. Nicolini et 
al. showed that complete necrosis was achieved in 
77% of tumors in the DEB group and only 27% of 
tumors in the bland embolization group [63]. 
Nevertheless, there are instances where there is 
incomplete/ineffective treatment because insufficient 
quantities of the embolic/drug are delivered and 
tumor resistance to the drug [14]. In addition, some 
investigators suggest that residual tumor cells can 
transform into a more malignant phenotype when 
there is incomplete tumor cell death [64, 65]. It is 
accepted that tumor heterogeneity contributes to 
different responses to monotherapy, which has 
promoted the development of combined therapies 
with TACE [66].  
Additionally, our work showed that 
SPECT/photoacoustic imaging mediated by 
131I-HCuSNPs-MS-PTX could help to confirm the 
delivery of the microspheres to the targeted tumors 
and to guide therapy planning for near-infrared laser 
irradiation. Previous studies have focused on embolic 
microsphere detection with CT and magnetic 
resonance (MR) imaging [67-69]; however, the high 
sensitivity of SPECT/CT and high specificity of 
photoacoustic imaging in our study obviated the need 
for additional imaging. 
Conclusions 
In this study, we synthesized and validated a 
combined therapeutic and imaging compound, 
131I-HCuSNPs-MS-PTX, for the treatment of the 
Walker-256 tumor transplanted into rat liver. IA 
injection of 131I-HCuSNPs-MS-PTX embolized the 
tumor vascular supply and delivered chemo-, photo- 
and radio-therapy locally and ablated the 
transplanted tumor. In addition, SPECT/CT and 
photoacoustic imaging of the microspheres confirmed 
that the embolized compound reached the targeted 
sites. We suggest that our findings offer the potential 
for using IA administration of 131I-HCuSNPs-MS-PTX 
in the clinic. 
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